CA3106484C - A salt of an lsd1 inhibitor and its crystal form - Google Patents
A salt of an lsd1 inhibitor and its crystal form Download PDFInfo
- Publication number
- CA3106484C CA3106484C CA3106484A CA3106484A CA3106484C CA 3106484 C CA3106484 C CA 3106484C CA 3106484 A CA3106484 A CA 3106484A CA 3106484 A CA3106484 A CA 3106484A CA 3106484 C CA3106484 C CA 3106484C
- Authority
- CA
- Canada
- Prior art keywords
- crystal form
- compound
- compound iii
- pattern
- present disclosure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810804068 | 2018-07-20 | ||
| CN201810804068.3 | 2018-07-20 | ||
| PCT/CN2019/096842 WO2020015745A1 (zh) | 2018-07-20 | 2019-07-19 | 一种lsd1抑制剂的盐及其晶型 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3106484A1 CA3106484A1 (en) | 2020-01-23 |
| CA3106484C true CA3106484C (en) | 2024-06-25 |
Family
ID=69163657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3106484A Active CA3106484C (en) | 2018-07-20 | 2019-07-19 | A salt of an lsd1 inhibitor and its crystal form |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12024494B2 (https=) |
| EP (1) | EP3825309B1 (https=) |
| JP (1) | JP7358466B2 (https=) |
| KR (1) | KR102778948B1 (https=) |
| CN (1) | CN112424175B (https=) |
| AU (1) | AU2019303777B2 (https=) |
| CA (1) | CA3106484C (https=) |
| WO (1) | WO2020015745A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021228146A1 (zh) * | 2020-05-12 | 2021-11-18 | 石药集团中奇制药技术（石家庄）有限公司 | 一种lsd1抑制剂的用途 |
| US20250073232A1 (en) | 2021-04-08 | 2025-03-06 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for treating myeloid cancers |
| EP4522136A1 (en) | 2022-05-09 | 2025-03-19 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| US20250295660A1 (en) | 2022-05-09 | 2025-09-25 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| CN116069221A (zh) * | 2022-12-27 | 2023-05-05 | 北京字跳网络技术有限公司 | 媒体内容的展示方法、装置、电子设备和存储介质 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2705675B1 (fr) * | 1993-05-27 | 1996-05-03 | Smithkline Beecham Labo Pharma | Nouveaux composés, leur procédé de préparation et leur utilisation en tant que médicaments. |
| US8993808B2 (en) * | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| CA2796726C (en) | 2010-04-19 | 2021-02-16 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| BR112013002164B1 (pt) * | 2010-07-29 | 2021-11-09 | Oryzon Genomics S.A. | Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica |
| PH12013501871A1 (en) | 2011-03-25 | 2019-06-03 | Glaxosmithkline Ip No 2 Ltd | Cyclopropylamines as lsd1 inhibitors |
| MY189367A (en) * | 2015-08-12 | 2022-02-08 | Incyte Corp | Salts of an lsd1 inhibitor |
| TWI833686B (zh) * | 2016-04-22 | 2024-03-01 | 美商英塞特公司 | Lsd1 抑制劑之調配物 |
| PT3455204T (pt) | 2016-05-09 | 2026-01-27 | Jubilant Epicore LLC | Compostos de ciclopropil-amida como inibidores duplos de lsd1/hdac |
| US11433053B2 (en) | 2017-01-24 | 2022-09-06 | Medshine Discovery Inc. | LSD1 inhibitor and preparation method and application thereof |
-
2019
- 2019-07-19 CA CA3106484A patent/CA3106484C/en active Active
- 2019-07-19 JP JP2021525358A patent/JP7358466B2/ja active Active
- 2019-07-19 WO PCT/CN2019/096842 patent/WO2020015745A1/zh not_active Ceased
- 2019-07-19 AU AU2019303777A patent/AU2019303777B2/en active Active
- 2019-07-19 CN CN201980047189.0A patent/CN112424175B/zh active Active
- 2019-07-19 KR KR1020217005112A patent/KR102778948B1/ko active Active
- 2019-07-19 US US17/261,322 patent/US12024494B2/en active Active
- 2019-07-19 EP EP19837636.0A patent/EP3825309B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3825309A1 (en) | 2021-05-26 |
| JP2021530565A (ja) | 2021-11-11 |
| AU2019303777A1 (en) | 2021-02-11 |
| EP3825309A4 (en) | 2022-03-23 |
| WO2020015745A1 (zh) | 2020-01-23 |
| EP3825309B1 (en) | 2023-09-06 |
| CA3106484A1 (en) | 2020-01-23 |
| KR102778948B1 (ko) | 2025-03-07 |
| CN112424175B (zh) | 2022-10-28 |
| JP7358466B2 (ja) | 2023-10-10 |
| KR20210034058A (ko) | 2021-03-29 |
| AU2019303777B2 (en) | 2023-01-19 |
| US12024494B2 (en) | 2024-07-02 |
| US20210317096A1 (en) | 2021-10-14 |
| CN112424175A (zh) | 2021-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3106484C (en) | A salt of an lsd1 inhibitor and its crystal form | |
| US12291536B2 (en) | Crystal form of Wee1 inhibitor compound and use thereof | |
| TW202128617A (zh) | 三苯化合物之新穎鹽類 | |
| TW202408510A (zh) | Ｃｄｋ抑制劑及其磷酸鹽的多晶型、其製備方法、包含其的醫藥組合物及其用途 | |
| RU2769050C1 (ru) | Кристаллическая форма и солевая форма соединения пиридоимидазола и соответствующий способ получения | |
| US8859567B2 (en) | Hydrate of 1-{(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di-hydropyrido[3,4-D]pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate | |
| BR112015017963A2 (pt) | composto de fenil amino pirimidina deuterado, método para preparar a composição farmacêutica, composição farmacêutica e uso do composto | |
| WO2021129589A1 (zh) | Kd-025的新晶型及其制备方法 | |
| EP3386956A1 (en) | Fumagillol derivatives and polymorphs thereof | |
| WO2022171044A1 (zh) | 一种氧氮杂螺环化合物、其盐型及其晶型 | |
| JP2024543921A (ja) | ＡＸＬキナーゼ阻害剤のモノ－ｐ－トルエンスルホン酸塩およびその結晶形 | |
| CN114728973B (zh) | 一种核蛋白抑制剂的晶型及其应用 | |
| RU2536685C2 (ru) | Фармацевтически приемлемые соли тимодепрессина и способ их получения | |
| RU2794977C2 (ru) | Соль ингибитора lsd1 и её полиморфная форма | |
| WO2024251230A1 (zh) | 一种plk1激酶抑制剂的盐型、晶型及其制备方法和应用 | |
| US20250197408A1 (en) | Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof | |
| HK40038512B (en) | Salt of lsd1 inhibitor and a polymorph thereof | |
| HK40038512A (en) | Salt of lsd1 inhibitor and a polymorph thereof | |
| WO2023093859A1 (zh) | Axl激酶抑制剂的盐、其制备方法和用途 | |
| US12391653B2 (en) | Salt form and crystal form of mutant IDH1 inhibitor and preparation method therefor | |
| US11708357B2 (en) | Crystal form of pyrrolidinyl urea derivative and application thereof | |
| WO2019057121A1 (zh) | 一种异喹啉磺酰衍生物的晶型及其制备方法 | |
| CN111484497B (zh) | 咪唑并[1,5-a]吡嗪类衍生物的可药用盐、晶型及其制备方法 | |
| WO2024213088A1 (zh) | 嘧啶三并环衍生物的结晶及用途 | |
| TW201938539A (zh) | 一種具有抗癌作用的化合物及其製備方法和應用（二） |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220329 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240719 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240719 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250616 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250617 |